Health Condition 1: M266- Temporomandibular joint disorders
Conditions
Interventions
Intervention1: Platelet-Rich Plasma (PRP): The study purpose will be fully explained to the parents /guardians, and a written consent will be taken authorizing enrolment of participants in the study.
Sponsors
Dr Hriti jain
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with myofascial pain involving the masseter muscle according to DC/TMD criteria, with a history of recurrent or chronic craniofacial musculoskeletal pain associated with trigger points, will be included in the study. Participants must undergo a pharmacological washout period of at least 72 hours for central analgesics, NSAIDs, and antidepressants prior to enrollment. Only those who provide informed consent will be considered. Additionally, a complete blood count (CBC) will be performed before PRP preparation, and only patients with normal hematological parameters will be included.
Exclusion criteria
Exclusion criteria: Patients with a documented history of allergy to local anesthetics, those currently on analgesics or anti-inflammatory medications who are unwilling to discontinue, and individuals undergoing physiotherapy or complementary and alternative medicine (CAM) for the same condition will be excluded. Patients showing radiographic evidence of bony changes, pregnant women, and those who are systemically compromised will also be excluded. Additionally, any patient unwilling to provide informed consent will not be considered for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)To evaluate the effectiveness of Platelet-Rich Plasma (PRP) injection in terms of pain intensity, pain-pressure threshold, and mouth opening in the management of Masseter muscle myalgia . 2)To evaluate the effectiveness of Local Anaesthetic (Lidocaine 2%) injection in terms of pain intensity, pain-pressure threshold, and mouth opening in the management of Masseter muscle myalgia . 3)To compare the effectiveness of trigger point injection of Platelet-Rich Plasma (PRP) and Local Anaesthetic (Lidocaine 2%) in the management of Masseter muscle myalgia . Timepoint: Follow up evaluation will be done on 5th day, 15th day ,30th day and 60th for pain intensity, pain pressure threshold and mouth opening. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To record any complications associated with trigger-point injections of Platelet-Rich Plasma (PRP) and Local Anaesthetic (2% lidocaine) as reported by the patients with Masseter muscle myalgia. 2.To assess the oral-health impact associated with Masseter muscle myalgia using the Oral Halth Impact Profile - TMD questionnaire.Timepoint: Follow up evaluation will be done on 5th day, 15th day ,30th day and 60th | — |
Countries
India
Contacts
Public ContactDr Ashita Kalaskar
Government Dental College and Hospital Nagpur
Outcome results
None listed